JAK1 and ovarian carcinoma: Our investigation revealed that TWP’s efficacy is driven by its ability to modulate five core targets—EGFR, JAK1, JAK2, PTPN11, and SRD5A1—which our analysis showed to be dysregulated in clinical ovarian cancer datasets.